Intravenous Iron Drugs Market Key Highlights:
- Market Size (2024): USD 1,516 Million
- Projected Market Size (2034): USD 2,288 Million
- CAGR (2023-2034): 4.2%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Intravenous Iron Drugs Market Definition
The intravenous iron drugs market deals in the manufacturing and distribution of iron deficiency therapeutics across the world. Various types of intravenous iron drugs are available in the market, including iron dextran, iron sucrose, ferric carboxymaltose, and others. Manufacturing these medicines involves several processes, such as complexation, isolation, drying, filtering, pH adjustment, and others. These drugs are mainly derived from iron oxyhydroxide cores surrounded by carbohydrate shells.
The rising incidences of chronic kidney diseases worldwide have increased the demand for intravenous iron drugs as these medications are used for dialysis patients, thereby driving the market growth. Also, the growing developments in HIF-inhibitor therapy, along with the increased application of intravenous iron injections in patients suffering from anemia, is another significant industry driver. Moreover, the growing use of these drugs in the treatment of cancer and inflammatory bowel diseases is likely to foster the growth of the intravenous iron drugs market.
The research and development activities associated with novel drug delivery systems and hepcidin modulation are expected to create ample growth opportunities for the market players in the upcoming days. In March 2024, Cadila Pharmaceuticals launched Redshot FCM. Redshot FCM is a novel iron injection developed to treat anemia.
Intravenous Iron Drugs Market Segmentation:
By Type
- Ferric Gluconate
- Ferric Carboxymaltose
- Iron Sucrose
- Iron Dextran
By Application
- Ferric Gluconate
- Ferric Carboxymaltose
- Iron Sucrose
- Iron Dextran
Intravenous Iron Drugs Market Companies:
- Allergan
- AMAG Pharmaceuticals
- Daiichi Sankyo
- Galenica
- Pharmacosmos
- Nippon Shinyaku
- NOXXON Pharma
- Rockwell Medical
- Sanofi
- Wanbang Biopharmaceutical.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
